The Cell Therapy Manufacturing Market is fragmented, with the presence of several players. Cell therapy involves the use of live cells as the medicinal product from the human or non-human source. Cell therapy or cell-based therapy utilizes cells as therapeutic agents in a number of diseases.
Market Overview:
Cell therapy manufacturing involves extraction of living cells from tissues or organs and isolation of specific type cells. These cells are then grown and multiplied in large numbers in a culture media before being infused or transplanted into patients. Cell therapy manufacturing provides better therapeutic alternatives for various diseases like cancer, neurological disorders, and cardiovascular diseases. With developments in regenerative medicine, there is growing demand for cell therapy worldwide which is boosting the growth of the global cell therapy manufacturing market.
Market key trends:
The global cell therapy manufacturing market is witnessing significant growth owing to increasing investments and funding for cell-based research. For instance, in 2020, the National Institutes of Health invested $1.51 billion in stem cell research. Furthermore, growing prevalence of chronic diseases such as cancer and increasing applications of regenerative medicine in the treatment of various diseases is expected to augment the market growth over the forecast period. Additionally, developments in cell culture media and rising adoption of automated cell therapy bioprocessing is anticipated to offer lucrative opportunities for market players. However, high costs associated with cell therapy manufacturing and stringent regulatory environment are some of the factors expected to restrain the market growth.
The global Cell Therapy Manufacturing Market Size is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Porter’s Analysis
Threat of new entrants: The high capital requirement for R&D, clinical trials, and manufacturing facilities poses a barrier to entry. Bargaining power of buyers: Individual consumers have less bargaining power due to lack of substitutes and life-saving nature of cell therapies. However, large pharmaceutical firms have significant bargaining power. Bargaining power of suppliers: A few innovative biotech firms control the intellectual property for specific cell therapies, giving them bargaining power over manufacturers. Threat of new substitutes: While alternative treatment options exist, cell therapies target diseases that have failed to respond to other therapeutics, limiting threat of substitutes. Competitive rivalry: Intense competition exists among large pharmaceutical firms to gain market share in high growth cell therapy segment through collaborations, acquisitions and new product launches.
SWOT Analysis
Strengths: Advanced cell culturing technologies, expertise in process development and regulatory affairs. Weaknesses: High costs associated with R&D and clinical trials. Risk of product failure or long development timelines.
Opportunities: High unmet medical needs. Favorable regulations and reimbursement. Collaborations to expand manufacturing capabilities.
Threats: Stringent regulatory approvals. Safety concerns regarding genomic modifications. Intellectual property disputes slowing commercialization.
Key Takeaways
The global cell therapy manufacturing market is expected to witness high growth, exhibiting CAGR of 15% over the forecast period, due to increasing prevalence of cancers and other chronic diseases. North America currently dominates the global market due to presence of advanced healthcare infrastructure and major market players.
Regional analysis Asia Pacific is fastest growing region in cell therapy manufacturing market driven by improving healthcare facilities, rising healthcare spending, and increasing initiatives by governments in countries such as China, Japan and India to develop local manufacturing facilities.
Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. The key players are focused on mergers and acquisitions to expand their geographic footprint.
